People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Technology, Robotics, Biotechnology, Biotech / Pharma, Software / Tech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zymergen Inc. | — | Other Technology | Growth/Late | $580.2M | $13.2B | 2015 |
| Scythe Robotics, Inc. | — | Robotics | Series C | $93.1M | $144.5M | 2020 |
| Enveda Therapeutics, Inc. | — | Biotechnology | Series C | $67.5M | $1.1B | 2020 |
| Diligent Robotics, Inc. | — | Robotics | Series C | $54.8M | $71.9M | 2023 |
| Prellis Biologics, Inc | — | Biotech / Pharma | Series B | $47.3M | $277.2M | 2017 |
| Seurat Technologies, Inc. | — | Software / Tech | Series C | $46.4M | $1.0B | 2016 |
| ATI Motors Inc. | — | Other Technology | Series B | $24.3M | $110.4M | 2024 |
| Vdopia Inc. | — | Other Technology | Series A | $8.1M | $94.1M | 2009 |
| Syfto, Inc. | — | Other | Seed | $2.4M | $28.8M | 2011 |
| Applied Biosensors, Inc.\DE | — | Other Technology | Pre-Seed | $675K | $5.7M | 2023 |
Rohit Sharma at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Rohit Sharma on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Marks | 1 | 20 |
| Andrew Lee | 1 | 14 |
| Dinesh Patel | 1 | 13 |
| Matt Ocko | 1 | 13 |
| Alex Morgan | 1 | 10 |
| Sameer Reddy | 1 | 7 |
| Richard Boyle | 1 | 6 |
| Paul Jansen | 1 | 3 |
| Zavain Dar | 1 | 3 |
| Quaeed Motiwala | 1 | 3 |
| Arvind Gupta | 1 | 3 |
| Tom Stephenson | 1 | 2 |
| Steven Chu | 1 | 2 |
| Shaun Holt | 1 | 2 |
| Zachariah Serber | 1 | 2 |
| Aaron Kimball | 1 | 2 |
| Herb Madan | 1 | 2 |
| Isaac Roberts | 1 | 2 |
| Lucy Deland | 1 | 2 |
| Duane Valz | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.